Peptide and protein drug delivery to and into tumors: challenges and solutions

Torchilin, Vladimir P.; Lukyanov, Anatoly N.

doi:10.1016/s1359-6446(03)02623-0

Cited by 324 publications

(238 citation statements)

References 66 publications

Supporting

Mentioning

229

Contrasting

Unclassified

Order By: Relevance

“…High-molecular-mass compounds as drug delivery vehicles recently attracted special attention because tumors can selectively accumulate these molecules by the enhanced permeability and retention (EPR) effect. It was observed in tumor tissue for macromolecules [7][8][9] and is used for cancer drug delivery. Tumor vasculature can be targeted with a synthetic polymer, N-(2-hydroxypropyl)methacrylamide [8], conjugated with O-(chloracetyl-carbamoyl) fumagillol (TNP-470) [10].…”

Section: Introductionmentioning

confidence: 99%

Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis

et al. 2006

View full text Add to dashboard Cite

We have previously shown that laminin-8, a vascular basement membrane component, was overexpressed in human glioblastomas multiforme and their adjacent tissues compared to normal brain. Increased laminin-8 correlated with shorter glioblastoma recurrence time and poor patient survival making it a potential marker for glioblastoma diagnostics and prediction of disease outcome. However, laminin-8 therapeutic potential was unknown because the technology of blocking the expression of multi-chain complex proteins was not yet developed. To inhibit the expression of laminin-8 constituents in glioblastoma in vitro and in vivo, we used Polycefin, a bioconjugate drug delivery system based on slime-mold Physarum polycephalum-derived poly(malic acid). It carries an attached transferrin receptor antibody to target tumor cells and to deliver two conjugated morpholino antisense oligonucleotides against laminin-8 α4 and β1 chains. and area (p < 0.001) and increased animal survival (p < 0.0004). These data suggest that laminin-8 may be important for glioblastoma angiogenesis. Polycefin, a versatile nanoscale drug delivery system, was suitable for in vivo delivery of two antisense oligonucleotides to brain tumor cells causing a reduction of glioblastoma angiogenesis and an increase of animal survival. This system may hold promise for future clinical applications.

show abstract

Section: Introductionmentioning

confidence: 99%

Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis

et al. 2006

View full text Add to dashboard Cite

show abstract

“…To establish efficient and reliable therapeutic drug delivery into cancer cells, a number of delivery agents have been investigated in recent years (16). Among these, applying cell-targeting peptides has emerged as the most valuable nonimmunogenic approach (11).…”

Section: Discussionmentioning

confidence: 99%

Targeting of Hepatoma Cell and Suppression of Tumor Growth by a Novel 12mer Peptide Fused to Superantigen TSST-1

Jiang

Wang

et al. 2006

Mol Med

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), one of the most common and malignant tumors worldwide, is unresponsive to any of the available therapies. Using intact HCC cells as therapeutic targets, we isolated a novel peptide, denoted HCC79 (KSLSRHDHIHHH), from a phage display peptide library. HCC79 can bind to hepatoma cell membranes with high affinity and specificity. Remarkably, competitive binding assays demonstrated that HCC79 competed with HAb25, a specific antibody for HCC, in binding to hepatoma cells. The corresponding synthetic peptide did not inhibit tumor proliferation directly, but repressed tumor invasion significantly in a cell migration assay. Moreover, we explored the potential of the selected peptide to deliver a superantigen (SAg) to cancer cells, to attain a significant cell-targeting effect. When the peptide is fused to the TSST-1 SAg, the resulting fusion protein could bind to hepatoma cells with high affinity in vitro and improved the tumor inhibition effect by activating T lymphocyte cells in vitro and in vivo, compared with TSST-1 alone. Taken together, our results indicate that this peptide and its future derivatives may have the potential to be developed into highly specific therapeutic agents against cancer.

show abstract

“…К настоя-щему времени для транспорта лекарственных препа-ратов были опробованы различные типы носителей: белки [5], мицеллы [6], липосомы [7] дендримеры [8], неорганические наночастицы [9][10][11][12][13][14] и др. Одни но-сители прошли этапы доклинических исследований, другие проходят различные фазы клинических испы-таний.…”

Section: экспериментальные статьиunclassified

The study of new anticancer drug delivery system based on the boron nitride nanoparticles

Житняк¹,

Сухорукова²,

Kovalskii³

et al. 2016

Usp. mol. onkol

View full text Add to dashboard Cite

Peptide and protein drug delivery to and into tumors: challenges and solutions

Cited by 324 publications

References 66 publications

Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis

Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis

Targeting of Hepatoma Cell and Suppression of Tumor Growth by a Novel 12mer Peptide Fused to Superantigen TSST-1

The study of new anticancer drug delivery system based on the boron nitride nanoparticles

Contact Info

Product

Resources

About